<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.0.2//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art502.dtd?><?SourceDTD.Version 5.0.2?><?ConverterInfo.XSLTName elsevier2nlm.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?FILEmeta_HRTHM3560 xml ?><?FILEmain xml ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><?FILEgr3 jpg ?><?FILEsi1 gif ?><front><journal-meta><journal-id journal-id-type="nlm-ta">Heart Rhythm</journal-id><journal-title>Heart Rhythm</journal-title><issn pub-type="ppub">1547-5271</issn><issn pub-type="epub">1556-3871</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">HRTHM3560</article-id><article-id pub-id-type="doi">10.1016/j.hrthm.2009.07.020</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Abnormal blood pressure response to exercise occurs more frequently in hypertrophic cardiomyopathy patients with the R92W troponin T mutation than in those with myosin mutations</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Heradien</surname><given-names>Marshall</given-names></name><xref rid="aff1" ref-type="aff">&#x0204e;</xref></contrib><contrib contrib-type="author"><name><surname>Revera</surname><given-names>Miriam</given-names></name><xref rid="aff2" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>van der Merwe</surname><given-names>Lize</given-names></name><xref rid="aff3" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Goosen</surname><given-names>Althea</given-names></name><xref rid="aff1" ref-type="aff">&#x0204e;</xref></contrib><contrib contrib-type="author"><name><surname>Corfield</surname><given-names>Valerie A.</given-names></name><xref rid="aff4" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author"><name><surname>Brink</surname><given-names>Paul A.</given-names></name><xref rid="aff3" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Mayosi</surname><given-names>Bongani M.</given-names></name><xref rid="aff5" ref-type="aff">&#x02016;</xref></contrib><contrib contrib-type="author"><name><surname>Moolman-Smook</surname><given-names>Johanna C.</given-names></name><email>HM@sun.ac.za</email><xref rid="aff4" ref-type="aff">&#x000a7;</xref><xref rid="aff5" ref-type="aff">&#x02016;</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib></contrib-group><aff id="aff1"><addr-line><sup>&#x0204e;</sup>Department of Internal Medicine, University of Stellenbosch Health Sciences Faculty, Tygerberg, South Africa</addr-line></aff><aff id="aff2"><addr-line><sup>&#x02020;</sup>Department of Cardiology, Istituto Di Ricovero E Cura A Carattere Scientifico San Matteo Hospital, Pavia, Italy</addr-line></aff><aff id="aff3"><addr-line><sup>&#x02021;</sup>Biostatistics Unit, Medical Research Council of South Africa, Tygerberg, South Africa</addr-line></aff><aff id="aff4"><addr-line><sup>&#x000a7;</sup>Medical Research Council/University of Stellenbosch Centre for Molecular and Cellular Biology, University of Stellenbosch Health Sciences Faculty, Tygerberg, South Africa</addr-line></aff><aff id="aff5"><addr-line><sup>&#x02016;</sup>Cardiovascular Genetics Laboratory, Hatter Institute for Cardiovascular Research, Department of Medicine, University of Cape Town, Cape Town, South Africa</addr-line></aff><author-notes><corresp id="cor1"><label>&#x0204e;</label><bold>Address reprint requests and correspondence:</bold> J. C. Moolman-Smook, MRC/US Centre for Molecular and Cellular Biology, Room 4036, University of Stellenbosch Health Sciences Faculty, Francie van Zijl Street, P.O. Box 19063, Tygerberg 7505, South Africa <email>HM@sun.ac.za</email></corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2009</year></pub-date><volume>6</volume><issue>11</issue><fpage>S18</fpage><lpage>S24</lpage><history/><permissions><copyright-statement>&#x000a9; 2009 Elsevier Inc..</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Heart Rhythm Society</copyright-holder><license><p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</p></license></permissions><abstract><p>Abnormal blood pressure response to exercise is reported to occur in up to a third of hypertrophic cardiomyopathy (HCM) cases and is associated with an increased risk of death, particularly in the young, but it is not known whether the HCM-causing mutation influences blood pressure response to exercise. The purpose of this article is to ascertain whether the blood pressure response to exercise differs among carriers of the R92W mutation in the cardiac troponin T gene (<italic>TNNT2</italic>), which has been associated with an increased risk of sudden cardiac death in young males; carriers of mutations in the cardiac &#x003b2;-myosin heavy chain gene (<italic>MYH7</italic>); and their noncarrier relatives. Thirty R92W<sub><italic>TNNT2</italic></sub> carriers, 51 <italic>MYH7</italic> mutation carriers, and 68 of their noncarrier relatives were subjected to bicycle ergonometric exercise testing to assess blood pressure response to, as well as heart rate recovery after, exercise. Additional echocardiographic and demographic details were documented for all participants. R92W<sub><italic>TNNT2</italic></sub> carriers demonstrated significantly more abnormal blood pressure responses to exercise (<italic>P</italic> = .021; odds ratio 3.03; confidence interval 1.13&#x02013;8.12) and smaller increases in systolic blood pressure than <italic>MYH7</italic> mutation carriers or related noncarrier control individuals. Although abnormal blood pressure response occurred at similar frequencies in males in all groups (23%&#x02013;26%), the percentage of R92W<sub><italic>TNNT2</italic></sub> females with abnormal blood pressure response was 64%, compared with 25% for <italic>MYH7</italic> and 22% for noncarriers. Therefore, these results show that blood pressure response to exercise is influenced by genotype and gender in patients with HCM.</p></abstract><kwd-group><title>Keywords</title><kwd>Hypertrophic cardiomyopathy</kwd><kwd>Abnormal blood pressure response</kwd><kwd>Survival</kwd><kwd>Troponin T</kwd><kwd>Beta-myosin</kwd><kwd>Genetic mutation</kwd></kwd-group><kwd-group><title>Abbreviations</title><kwd>Ca<sup>2+</sup>, calcium</kwd><kwd>CR, chronotropic response</kwd><kwd>DBP, diastolic blood pressure</kwd><kwd>ECG, electrocardiogram</kwd><kwd>HCM, hypertrophic cardiomyopathy</kwd><kwd>HR, heart rate</kwd><kwd>LV, left ventricle</kwd><kwd>LVM, left ventricular mass</kwd><kwd>maxLVWT, maximum left ventricular wall thickness</kwd><kwd>METs, metabolic equivalents</kwd><kwd><italic>MYH7</italic>, beta cardiac myosin heavy chain gene</kwd><kwd>SBP, systolic blood pressure</kwd><kwd>SCD, sudden cardiac death</kwd><kwd><italic>TNNT2</italic>, cardiac troponin T gene</kwd></kwd-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Hypertrophic cardiomyopathy (HCM), a primary cardiac muscle disease with 0.2% prevalence,<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> is characterized primarily by thickening of the ventricular wall in the absence of other hypertrophy-predisposing conditions<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> and by an increased risk for sudden cardiac death (SCD), which may relate to changes in cardiac energy and/or Ca<sup>2+</sup> homeostasis or histopathological changes in the myocardium.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> HCM is typically caused by mutations in genes encoding protein components of the cardiac sarcomere (<ext-link xlink:href="http://genetics.med.harvard.edu/~seidman/cg3/index.html" ext-link-type="uri">http://genetics.med.harvard.edu/&#x0223c;seidman/cg3/index.html</ext-link>), with the three most common causes being mutations in the genes encoding beta cardiac myosin heavy chain (<italic>MYH7</italic>), cardiac troponin T (<italic>TNNT2</italic>), and myosin binding protein C. Although the phenotypes resulting from these genetic defects vary greatly, mutations in <italic>TNNT2</italic> in humans<xref rid="bib3 bib4" ref-type="bibr"><sup>3,4</sup></xref> and in animal models<xref rid="bib5 bib6" ref-type="bibr"><sup>5,6</sup></xref> have frequently resulted in an increased susceptibility to SCD, often in the presence of mild or absent cardiac hypertrophy. We have previously reported an increased frequency of SCD, affecting young males in particular, in HCM families in which the R92W mutation in <italic>TNNT2</italic> segregates,<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> although the reason for this poor prognosis was not investigated at the time.</p><p>Blood pressure response to exercise testing is commonly used as an indicator of risk for SCD in patients with HCM. The failure of blood pressure to increase appropriately in response to exercise has been recorded in 8%&#x02013;33% of ungenotyped patients with HCM.<xref rid="bib8 bib9 bib10" ref-type="bibr"><sup>8&#x02013;10</sup></xref> Abnormal blood pressure responses have been associated with an increase in cardiovascular mortality<xref rid="bib8 bib11" ref-type="bibr"><sup>8,11</sup></xref> and have a reported 15% positive predictive value for SCD in HCM.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> It is not known whether the blood pressure response to exercise in HCM is influenced by genotype.</p><p>We hypothesized that the R92W mutation, which confers a high rate of SCD, may be associated with an abnormal blood pressure response to exercise. Here we investigated this hypothesis by comparing the blood pressure response to exercise in carriers of the R92W<sub><italic>TNNT2</italic></sub> mutation with that of carriers of HCM-causing mutations in the cardiac &#x003b2;-<italic>MYH7</italic> mutations (A797T and R403W) and noncarrier relatives.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref></p></sec><sec sec-type="methods" id="sec2"><title>Methods</title><sec id="sec2.1"><title>Subjects</title><p>The study was approved by the Institutional Review Board of the University of Stellenbosch Health Sciences Faculty (N04/03/062). Individuals belonging to consecutively identified HCM families in which either of three founder HCM-causing mutations segregate (R92W<sub><italic>TNNT2</italic></sub>, A797T<sub><italic>MYH7</italic></sub>, R403W<sub><italic>MYH7</italic></sub>)<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> who did not have pacemakers, who were in sinus rhythm at the time of the exercise test, and who gave written informed consent were included in this study.</p><p>A medical and family history was taken, and age, sex, height, and weight as well as sudden death events that had occurred in family members were recorded for each participant. Only sudden deaths occurring in genotyped mutation carriers, or obligate heterozygotes, or individuals with a diagnosis of HCM, or with a history of syncope were considered as SCDs. Blood pressure was taken twice in the sitting position, after 5 minutes of bed rest, and the second measurement was used. Individuals were coded as hypertensive if they on more than one occasion had systolic blood pressure (SBP) &#x02265;140 mmHg or diastolic blood pressure (DBP) &#x02265;90 or were on antihypertensive medication.</p></sec><sec id="sec2.2"><title>Exercise testing</title><p>We performed 12-lead electrocardiography (ECG) on a MAC 1200ST machine after 5 minutes of rest in the supine position and from this determined a resting heart rate (HR) and whether normal sinus rhythm was present. All cardioactive medications were discontinued for at least 5 pharmacokinetic half-lives before exercise testing. Exercise testing was performed by practitioners who were blinded to the genotype status of the participants.</p><p>Maximum symptom-limited bicycle ergonometric exercise testing was performed according to the following protocol: eight stages over 24 minutes with incremental increase of 25 W every 2 minutes (25&#x02013;200 W). Concurrent continuous 12-lead ECG monitoring was performed with the Norav Medical System. SBP and DBP were recorded with a mercury sphygmomanometer by a trained nurse (AG). Blood pressure values were recorded at rest, at 1-minute intervals during exercise, and at 1-minute intervals for 5 minutes during the recovery period.</p><p>We recorded the maximal workload achieved (in metabolic equivalents [METs]), total exercise time (in minutes and seconds), the maximum SBP and DBP achieved during exercise, the SBP and DBP and HR at peak exercise and at 1-minute intervals during recovery, and the percentage of predicted maximal HR for age and sex achieved by peak exercise. The predicted maximal HR was calculated as 220 minus age for men and 210 minus age for women.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> Chronotropic reserve (CR) was calculated as described elsewhere.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref></p><p>Normal blood pressure response was defined as an increase of at least 20 mmHg in SBP during exercise, with a gradual decline during recovery.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> Abnormal blood pressure responses were defined as either (1) an initial increase in SBP with a subsequent fall of &#x0003e;20 mmHg compared with the blood pressure value at peak exercise or a continuous decrease in SBP throughout the exercise test of &#x0003e;20 mmHg compared with resting blood pressure (termed hypotensive responses) or (2) an increase of &#x0003c;20 mmHg in SBP from resting state to peak exercise (termed a flat response).</p><p>Exercise was terminated for any of the following reasons: reaching target HR, fatigue, severe dyspnea, significant chest pain, near syncope, or development of arrhythmias.</p></sec><sec id="sec2.3"><title>Echocardiography</title><p>Echocardiography was performed on all participating individuals, using a standardized procedure, by a single experienced echocardiographer (MR) who was blinded to mutation status. A GE Healthcare Vivid7 cardiovascular ultrasound system was used to determine maximum wall thickness at 16 left ventricular (LV) wall segments on M-mode and two-dimensional images, as described elsewhere.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> Overall maximum LV wall thickness (maxLVWT) was recorded for each individual.</p><p>LV mass (LVM) was calculated using the American Society of Echocardiography formula for estimation of LVM from two-dimensional LV linear dimensions as described elsewhere.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> Ejection fraction was determined by the biplane method of discs, using the modified Simpson's rule, while fractional shortening was calculated using LV diastolic and systolic diameters from two-dimensional echocardiography images.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> Stroke volume was calculated as<disp-formula id="eq1"><mml:math id="M1" altimg="si1.gif" overflow="scroll"><mml:mrow><mml:mi>S</mml:mi><mml:mi>V</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mrow><mml:mn>7</mml:mn><mml:mo>/</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2.4</mml:mn><mml:mo>+</mml:mo><mml:mtext>LVd</mml:mtext></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:mtext>L</mml:mtext><mml:mtext>V</mml:mtext><mml:msup><mml:mtext>d</mml:mtext><mml:mn>3</mml:mn></mml:msup></mml:mrow></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mrow><mml:mn>7</mml:mn><mml:mo>/</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2.4</mml:mn><mml:mo>+</mml:mo><mml:mtext>LVs</mml:mtext></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x000d7;</mml:mo><mml:msup><mml:mrow><mml:mtext>LVs</mml:mtext></mml:mrow><mml:mn>3</mml:mn></mml:msup></mml:mrow></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula></p><p>where LVd = LV end-diastolic diameter and LVs = LV end-systolic diameter. Cardiac output was calculated as CO <italic>=</italic> (SV &#x000d7; HR)/100, where SV is stroke volume and HR is resting HR.</p><p>LV outflow obstruction was considered to be present when a peak instantaneous subaortic gradient &#x02265;30 mmHg was estimated with continuous wave Doppler echocardiography under resting conditions.<xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> Mitral regurgitation was graded semiquantitatively (1&#x02013;4+ scale).<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref></p></sec><sec id="sec2.4"><title>Statistical analyses</title><p>Comparisons were made among three groups consisting of noncarriers, carriers of the R92W<sub><italic>TNNT2</italic></sub>, and carriers of either of the <italic>MYH7</italic> mutations. Quantitative variables were quantile normalized before modeling.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> As the distribution of age, gender, body size, and resting hemodynamic parameters varied between groups, these factors were adjusted for in statistical comparisons of the hemodynamic responses during exercise between groups. General (quantitative) and generalized (dichotomous, categorical) linear mixed-effects models were used, as required, with adjustment for family relatedness as random factor (R package). <italic>P</italic> &#x0003c;.05 was considered statistically significant.</p></sec></sec><sec id="sec3"><title>Results</title><p>Thirty R92W<sub><italic>TNNT2</italic></sub> carriers from seven families, 51 <italic>MYH7</italic> mutation carriers (27 A797T<sub><italic>MYH7</italic></sub> carriers from 10 families, 24 R403W<sub><italic>MYH7</italic></sub> carriers from three families) and 68 of their noncarrier relatives participated in exercise testing. The relevant clinical and demographic characteristics of these individuals are given in <xref rid="tbl1" ref-type="table">Table 1</xref>. Total exercise time, workload, and percentage of target HR achieved were similar between groups (<xref rid="tbl2" ref-type="table">Table 2</xref>). In the R92W<sub><italic>TNNT2</italic></sub> families, SCD had affected predominantly young males (eight males, age at SCD 22.5 &#x000b1; 10 years [mean &#x000b1; standard deviation]; one female, 62 years; <xref rid="tbl3" ref-type="table">Table 3</xref>). Among <italic>MYH7</italic> mutation carriers, five male (mean age at SCD 35.8 &#x000b1; 17.3 years) and three female (mean age at SCD 32 &#x000b1; 20.2 years) A797T<sub><italic>MYH7</italic></sub> carriers experienced SCD before the study. At least five of the <italic>MYH7</italic> and all R92W<sub><italic>TNNT2</italic></sub> SCDs had occurred during periods of physical activity or emotional excitement (<xref rid="tbl3" ref-type="table">Table 3</xref>). One SCD in each of the R92W<sub><italic>TNNT2</italic></sub> and <italic>MYH7</italic> groups occurred in females &#x0003e;40 years.</p><p>Whereas abnormal blood pressure response to exercise occurred in about a quarter of control individuals or individuals carrying either <italic>MYH7</italic> mutation, this phenomenon was present in significantly more, that is, nearly half, of R92W<sub><italic>TNNT2</italic></sub> carriers (<xref rid="tbl2" ref-type="table">Table 2</xref>). No individuals demonstrated a continuous decrease in SBP throughout the exercise test. Flat abnormal blood pressure responses predominated in all groups but were the only type of abnormal blood pressure response in R92W<sub><italic>TNNT2</italic></sub> carriers (<xref rid="tbl2" ref-type="table">Table 2</xref>). Statistical analysis indicated that R92W<sub><italic>TNNT2</italic></sub> carriers were 3 times as likely to demonstrate an abnormal blood pressure response to exercise compared with either <italic>MYH7</italic> mutation carriers or noncarrier control individuals (<xref rid="tbl4" ref-type="table">Table 4</xref>). This was particularly noticeable for female R92W<sub><italic>TNNT2</italic></sub> carriers (<xref rid="fig1" ref-type="fig">Figure 1</xref>); the percentage of females with abnormal blood pressure response for R92W<sub><italic>TNNT2</italic></sub> was 64%, for <italic>MYH7</italic> 25%, and for noncarriers 22%. In contrast, the percentage of males with abnormal blood pressure response was similar for the three groups (R92W<sub><italic>TNNT2</italic></sub> 24%; <italic>MYH7</italic> 23%; noncarriers 26%).</p><p>After adjustment for age, sex, resting mean arterial pressure, and resting HR, the effect of exercise on HR and DBP parameters (<xref rid="tbl2" ref-type="table">Table 2</xref>) was not different between groups. However, R92W<sub><italic>TNNT2</italic></sub> carriers achieved a significantly lower mean SBP at peak exercise, as well as a smaller mean change (<xref rid="tbl2" ref-type="table">Table 2</xref>) and a smaller percentage of change in SBP (<xref rid="fig2" ref-type="fig">Figure 2</xref>) between resting and peak exercise, than did noncarriers and <italic>MYH7</italic> mutation carriers.</p><p>Interestingly, we also observed that, while the mean rate of SBP change increased in the first 3 minutes of exercise in the control and <italic>MYH7</italic> groups, R92W<sub><italic>TNNT2</italic></sub> carriers on average demonstrated a slight decrease in the rate at which SBP changed during the first 3 minutes of exercise (<xref rid="fig3" ref-type="fig">Figure 3</xref>). However, perhaps owing to the small numbers of individuals involved, this difference was not statistically significant.</p></sec><sec id="sec4"><title>Discussion</title><p>Abnormal blood pressure response to exercise has been associated with HCM-related death, with patients &#x0003c;50 years old showing a fourfold increase in premature HCM-related death.<xref rid="bib8 bib11" ref-type="bibr"><sup>8,11</sup></xref> However, it is unknown whether abnormal blood pressure response is influenced by the HCM-causing genotype. Here we show that individuals carrying the R92W<sub><italic>TNNT2</italic></sub> mutation are 3 times as likely to experience abnormal blood pressure response upon exercise compared with those carrying either of two <italic>MYH7</italic> mutations or noncarrier controls.</p><p>We have previously described an increased frequency of SCD, predominantly affecting young males in their teenage years, in two ancestrally related families in which the R92W<sub><italic>TNNT2</italic></sub> mutation segregates.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> In this study, we report SCDs in a further two of five additional R92W<sub><italic>TNNT2</italic></sub> families identified (<xref rid="tbl3" ref-type="table">Table 3</xref>); these families have been shown by genetic haplotype analysis (data not shown) to be ancestrally related to the original two R92W<sub><italic>TNNT2</italic></sub> families.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> While SCD had occurred in four (57%) of the seven R92W<sub><italic>TNNT2</italic></sub> families, predominantly affecting young men in their teenage years, SCD in <italic>MYH7</italic> families was limited to those in which the A797T<sub><italic>MYH7</italic></sub> mutation segregates (five [50%] of 10 A797T<sub><italic>MYH7</italic></sub> families, 39% of total <italic>MYH7</italic> families) and mostly affected adult individuals (<xref rid="tbl3" ref-type="table">Table 3</xref>). Similar to our first report of the clinical picture associated with R92W<sub><italic>TNNT2</italic></sub> carriers, overt hypertrophy was a rare occurrence in the R92W<sub><italic>TNNT2</italic></sub> group<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> but occurred more frequently in the <italic>MYH7</italic> group (n = 4, all A797T<sub><italic>MYH7</italic></sub> carriers), while syncope occurred at comparable levels in both mutation groups (<xref rid="tbl1" ref-type="table">Table 1</xref>).</p><p>We found that carriers of the R92W<sub><italic>TNNT2</italic></sub> mutation demonstrate abnormal blood pressure response to exercise significantly more frequently (<xref rid="tbl2 tbl4" ref-type="table">Tables 2 and 4</xref>; <italic>P</italic> = .021, odds ratio = 3.03) and show smaller absolute (&#x00394;SBP, <xref rid="tbl2" ref-type="table">Table 2</xref>) and relative (% change from resting SBP, <xref rid="fig2" ref-type="fig">Figure 2</xref>) changes in SBP than do carriers of <italic>MYH7</italic> mutations or related noncarrier control individuals. Thus, our study of the largest number of cases with an identical mutation in the <italic>TNNT2</italic> gene to date provides strong evidence for the influence of genotype on hemodynamic response in HCM.</p><p>In R92W<sub><italic>TNNT2</italic></sub> carriers, abnormal blood pressure responses were always of the flat type, namely, a failure to increase SBP by &#x0003e;20 mmHg between resting and peak exercise state. This finding, as well as the smaller increases in SBP observed in this study in the R92W<sub><italic>TNNT2</italic></sub> group during exercise (<xref rid="tbl2" ref-type="table">Table 2</xref>, <xref rid="fig1" ref-type="fig">Figure 1</xref>), supports the results of Sakata et al,<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> who recently reported that a group consisting of carriers of diverse troponin mutations demonstrated a smaller increase in SBP during exercise than did individuals without troponin mutations.</p><p>The mechanisms underlying abnormal blood pressure response to exercise in HCM are not yet completely understood. While some studies indicate that this response is due to an exaggerated decrease in systemic vascular resistance,<xref rid="bib9 bib21" ref-type="bibr"><sup>9,21</sup></xref> other studies suggest that impaired cardiac output is responsible for exercise hypotension.<xref rid="bib22 bib23" ref-type="bibr"><sup>22,23</sup></xref> Although it remains possible that either or a combination of both mechanisms are at play in subsets of HCM patients,<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> Sakata et al<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> found that systemic vascular resistance decreased to a similar extent in the <italic>TNNT2</italic> and non-<italic>TNNT2</italic> groups. They proposed that their findings related to the systolic dysfunction, which would result in decreased cardiac output that developed only in the <italic>TNNT2</italic> group during exercise.</p><p>The development of abnormal blood pressure response may also be related to autonomic control, as studies of neurotransmitter levels before and after exercise have also previously indicated that HCM patients manifest a sympathoadrenal imbalance during exercise.<xref rid="bib25 bib26" ref-type="bibr"><sup>25,26</sup></xref> The cause of this imbalance is not known, nor is it known whether this imbalance is genotype related, but it has been suggested that the enhanced systolic function that occurs under resting conditions in transgenic mutant <italic>TNNT2</italic> mice,<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> as well as in prehypertrophic R92W<sub><italic>TNNT2</italic></sub> carriers,<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> may activate ventricular mechanoreceptors and cause chronic alterations in vagal tone. On the other hand, Kawasaki et al<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> recently demonstrated that subendocardial ischemia, which occurs in about 50% of HCM patients upon exercise,<xref rid="bib23 bib28" ref-type="bibr"><sup>23,28</sup></xref> leads to vagal enhancement in patients with HCM, which may be related to the development of abnormal blood pressure response to exercise.</p><p>The preponderance of abnormal blood pressure response in females in the R92W<sub><italic>TNNT2</italic></sub> group might be explained by vagal enhancement, which results from either mechanism proposed above, occurring on the background of the normally predominantly parasympathetically biased cardiac regulation in females.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> The preponderance of abnormal blood pressure response in female R92W<sub><italic>TNNT2</italic></sub> carriers, who experience less SCD than their male counterparts, could suggest that this hemodynamic factor is not causally associated with the high frequency of sudden death with exercise that we have observed in the R92W<sub><italic>TNNT2</italic></sub> group. However, in light of previous longitudinal studies indicating an increase in premature HCM-related death among HCM patients demonstrating abnormal blood pressure response to exercise,<xref rid="bib8 bib11" ref-type="bibr"><sup>8,11</sup></xref> the survival and abnormal blood pressure response data in this study may suggest that a parasympathetic shift is not well tolerated in the predominantly sympathetically regulated male hearts.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref></p><p>Failure to increase SBP appropriately during exercise is indicative of severe coronary artery disease in the general population<xref rid="bib30 bib31" ref-type="bibr"><sup>30,31</sup></xref> and is more marked for those who fail to increase SBP appropriately during the first 3 minutes of exercise rather than later on during exercise.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> This is interesting, given our preliminary observation of the rate of change in SBP, which suggests that individuals with the R92W<sub><italic>TNNT2</italic></sub> mutation may fail to increase blood pressure appropriately, particularly early on during exercise (<xref rid="fig3" ref-type="fig">Figure 3</xref>).</p><p>In contrast to the high rate of abnormal blood pressure response to exercise in the R92W<sub><italic>TNNT2</italic></sub> group, the frequency of abnormal blood pressure response to exercise in the <italic>MYH7</italic> group was similar to that reported for genotype-unknown HCM patients<xref rid="bib8 bib9" ref-type="bibr"><sup>8,9</sup></xref> and was equal to that observed in the control group of noncarrier relatives (62% from <italic>MYH7</italic> and 38% from R92W<sub><italic>TNNT2</italic></sub> families). However, the frequency of abnormal blood pressure response to exercise in this control group was much higher than that reported for a non&#x02013;South African general population (2%&#x02013;8%).<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> The reason for this is not immediately clear; however, half of the control individuals with abnormal blood pressure response in this study were overweight or obese (body mass index &#x0003e;25), perhaps indicating a risk for coronary artery disease and silent myocardial ischemia.<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> Other reported causes of an abnormal blood pressure response to exercise include valvular heart disease, orthostatic hypotension, and the use of drugs such as vasodilators, negative inotropic agents, and diuretics.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref></p></sec><sec id="sec5"><title>Conclusion</title><p>Individuals with R92W<sub><italic>TNNT2</italic></sub> mutations demonstrate abnormal blood pressure response to exercise significantly more frequently than do individuals with <italic>MYH7</italic> mutations or noncarrier controls, indicating that abnormal blood pressure response is influenced by genotype. The preponderance of female R92W<sub><italic>TNNT2</italic></sub> carriers with abnormal blood pressure response, with a lower risk of SCD than affected males, supports the suggestion that abnormal blood pressure response may be associated with a parasympathetic shift in the regulation of cardiac function and that parasympathetic shifts are not well tolerated in predominantly sympathetically regulated male hearts. Although implantable defibrillators are the most effective life-saving therapy available for prevention of SCD in HCM, this option is not widely available outside of developed nations owing to cost. Elucidating the molecular mechanisms underlying SCD in HCM may eventually facilitate development of alternative effective therapeutic options.</p></sec></body><back><ack><title>Acknowledgment</title><p>The authors thank Peter Doubell for his help in collating the data.</p></ack><fn-group><fn id="N0x1d05aa0N0x2a968f0"><p>The first two authors contributed equally to this work.</p></fn><fn id="N0x1d05aa0N0x2a969b0"><p>This study was funded by a Wellcome Trust International Senior Research Fellowship.</p></fn><fn id="N0x1d05aa0N0x2a96a70"><p>The Vivid 7 cardiovascular ultrasound system was provided <italic>pro bono</italic> by GE Healthcare (Germany) for the duration of the study.</p></fn><fn id="N0x1d05aa0N0x2a96b90"><p>None of the authors have any conflict of interest to disclose.</p></fn></fn-group><ref-list><title>References</title><ref id="bib1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maron</surname><given-names>B.J.</given-names></name><name><surname>Gardin</surname><given-names>J.M.</given-names></name><name><surname>Flack</surname><given-names>J.M.</given-names></name></person-group><article-title>Prevalence of hypertrophic cardiomyopathy in a general population of young adults</article-title><source>Circulation</source><year>1995</year><volume>92</volume><fpage>785</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">7641357</pub-id></citation></ref><ref id="bib2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>P.</given-names></name><name><surname>McKenna</surname><given-names>W.J.</given-names></name></person-group><article-title>Hypertrophic cardiomyopathy</article-title><source>Lancet</source><year>2004</year><volume>363</volume><fpage>1881</fpage><lpage>1891</lpage><pub-id pub-id-type="pmid">15183628</pub-id></citation></ref><ref id="bib3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Watkins</surname><given-names>H.</given-names></name><name><surname>McKenna</surname><given-names>W.J.</given-names></name><name><surname>Thierfelder</surname><given-names>L.</given-names></name></person-group><article-title>Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy</article-title><source>N Engl J Med</source><year>1995</year><volume>332</volume><fpage>1058</fpage><lpage>1064</lpage><pub-id pub-id-type="pmid">7898523</pub-id></citation></ref><ref id="bib4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Varnava</surname><given-names>A.M.</given-names></name><name><surname>Elliott</surname><given-names>P.M.</given-names></name><name><surname>Baboonian</surname><given-names>C.</given-names></name></person-group><article-title>Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease</article-title><source>Circulation</source><year>2001</year><volume>104</volume><fpage>1380</fpage><lpage>1384</lpage><pub-id pub-id-type="pmid">11560853</pub-id></citation></ref><ref id="bib5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tardiff</surname><given-names>J.C.</given-names></name><name><surname>Hewett</surname><given-names>T.E.</given-names></name><name><surname>Palmer</surname><given-names>B.M.</given-names></name></person-group><article-title>Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy</article-title><source>J Clin Invest</source><year>1999</year><volume>104</volume><fpage>469</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">10449439</pub-id></citation></ref><ref id="bib6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ertz-Berger</surname><given-names>B.R.</given-names></name><name><surname>He</surname><given-names>H.</given-names></name><name><surname>Dowell</surname><given-names>C.</given-names></name></person-group><article-title>Changes in the chemical and dynamic properties of cardiac troponin T cause discrete cardiomyopathies in transgenic mice</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><fpage>18219</fpage><lpage>18224</lpage><pub-id pub-id-type="pmid">16326803</pub-id></citation></ref><ref id="bib7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moolman</surname><given-names>J.C.</given-names></name><name><surname>Corfield</surname><given-names>V.A.</given-names></name><name><surname>Posen</surname><given-names>B.</given-names></name></person-group><article-title>Sudden death due to troponin T mutations</article-title><source>J Am Coll Cardiol</source><year>1997</year><volume>29</volume><fpage>549</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">9060892</pub-id></citation></ref><ref id="bib8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olivotto</surname><given-names>I.</given-names></name><name><surname>Maron</surname><given-names>B.J.</given-names></name><name><surname>Montereggi</surname><given-names>A.</given-names></name></person-group><article-title>Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy</article-title><source>J Am Coll Cardiol</source><year>1999</year><volume>33</volume><fpage>2044</fpage><lpage>2051</lpage><pub-id pub-id-type="pmid">10362212</pub-id></citation></ref><ref id="bib9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frenneaux</surname><given-names>M.P.</given-names></name><name><surname>Counihan</surname><given-names>P.J.</given-names></name><name><surname>Caforio</surname><given-names>A.L.</given-names></name></person-group><article-title>Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy</article-title><source>Circulation</source><year>1990</year><volume>82</volume><fpage>1995</fpage><lpage>2002</lpage><pub-id pub-id-type="pmid">2242524</pub-id></citation></ref><ref id="bib10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawasaki</surname><given-names>T.</given-names></name><name><surname>Azuma</surname><given-names>A.</given-names></name><name><surname>Kuribayashi</surname><given-names>T.</given-names></name></person-group><article-title>Vagal enhancement due to subendocardial ischemia as a cause of abnormal blood pressure response in hypertrophic cardiomyopathy</article-title><source>Int J Cardiol</source><year>2008</year><volume>129</volume><fpage>59</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">17651826</pub-id></citation></ref><ref id="bib11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sadoul</surname><given-names>N.</given-names></name><name><surname>Prasad</surname><given-names>K.</given-names></name><name><surname>Elliott</surname><given-names>P.M.</given-names></name></person-group><article-title>Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy</article-title><source>Circulation</source><year>1997</year><volume>96</volume><fpage>2987</fpage><lpage>2991</lpage><pub-id pub-id-type="pmid">9386166</pub-id></citation></ref><ref id="bib12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moolman-Smook</surname><given-names>J.C.</given-names></name><name><surname>De Lange</surname><given-names>W.J.</given-names></name><name><surname>Bruwer</surname><given-names>E.C.</given-names></name></person-group><article-title>The origins of hypertrophic cardiomyopathy-causing mutations in two South African subpopulations: a unique profile of both independent and founder events</article-title><source>Am J Hum Genet</source><year>1999</year><volume>65</volume><fpage>1308</fpage><lpage>1320</lpage><pub-id pub-id-type="pmid">10521296</pub-id></citation></ref><ref id="bib13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Revera</surname><given-names>M.</given-names></name><name><surname>Van Der</surname><given-names>M.L.</given-names></name><name><surname>Heradien</surname><given-names>M.</given-names></name></person-group><article-title>Troponin T and beta-myosin mutations have distinct cardiac functional effects in hypertrophic cardiomyopathy patients without hypertrophy</article-title><source>Cardiovasc Res</source><year>2008</year><volume>77</volume><fpage>687</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">18029407</pub-id></citation></ref><ref id="bib14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bruce</surname><given-names>R.A.</given-names></name><name><surname>McDonough</surname><given-names>J.R.</given-names></name></person-group><article-title>Stress testing in screening for cardiovascular disease</article-title><source>Bull N Y Acad Med</source><year>1969</year><volume>45</volume><fpage>1288</fpage><lpage>1305</lpage><pub-id pub-id-type="pmid">5261245</pub-id></citation></ref><ref id="bib15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nanas</surname><given-names>S.</given-names></name><name><surname>Nastasiou-Nana</surname><given-names>M.</given-names></name><name><surname>Dimopoulos</surname><given-names>S.</given-names></name></person-group><article-title>Early heart rate recovery after exercise predicts mortality in patients with chronic heart failure</article-title><source>Int J Cardiol</source><year>2006</year><volume>110</volume><fpage>393</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">16371237</pub-id></citation></ref><ref id="bib16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schiller</surname><given-names>N.B.</given-names></name><name><surname>Shah</surname><given-names>P.M.</given-names></name><name><surname>Crawford</surname><given-names>M.</given-names></name></person-group><article-title>Recommendations for quantitation of the left ventricle by two-dimensional echocardiography</article-title><source>J Am Soc Echocardiogr</source><year>1989</year><volume>2</volume><fpage>358</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">2698218</pub-id></citation></ref><ref id="bib17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maron</surname><given-names>M.S.</given-names></name><name><surname>Olivotto</surname><given-names>I.</given-names></name><name><surname>Betocchi</surname><given-names>S.</given-names></name></person-group><article-title>Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><fpage>295</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">12540642</pub-id></citation></ref><ref id="bib18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sobel</surname><given-names>E.</given-names></name><name><surname>Sengul</surname><given-names>H.</given-names></name><name><surname>Weeks</surname><given-names>D.E.</given-names></name></person-group><article-title>Multipoint estimation of identity-by-descent probabilities at arbitrary positions among marker loci on general pedigrees</article-title><source>Hum Hered</source><year>2001</year><volume>52</volume><fpage>121</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">11588394</pub-id></citation></ref><ref id="bib19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pilia</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>W.M.</given-names></name><name><surname>Scuteri</surname><given-names>A.</given-names></name></person-group><article-title>Heritability of cardiovascular and personality traits in 6,148 Sardinians</article-title><source>PLoS Genet</source><year>2006</year><volume>2</volume><fpage>e132</fpage><pub-id pub-id-type="pmid">16934002</pub-id></citation></ref><ref id="bib20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakata</surname><given-names>K.</given-names></name><name><surname>Ino</surname><given-names>H.</given-names></name><name><surname>Scuteri</surname><given-names>N.</given-names></name></person-group><article-title>Exercise-induced systolic dysfunction in patients with non-obstructive hypertrophic cardiomyopathy and mutations in the cardiac troponin genes</article-title><source>Heart</source><year>2008</year><volume>94</volume><fpage>1282</fpage><lpage>1287</lpage><pub-id pub-id-type="pmid">17923468</pub-id></citation></ref><ref id="bib21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Counihan</surname><given-names>P.J.</given-names></name><name><surname>Frenneaux</surname><given-names>M.P.</given-names></name><name><surname>Webb</surname><given-names>D.J.</given-names></name></person-group><article-title>Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy</article-title><source>Circulation</source><year>1991</year><volume>84</volume><fpage>686</fpage><lpage>696</lpage><pub-id pub-id-type="pmid">1860213</pub-id></citation></ref><ref id="bib22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ciampi</surname><given-names>Q.</given-names></name><name><surname>Betocchi</surname><given-names>S.</given-names></name><name><surname>Lombardi</surname><given-names>R.</given-names></name></person-group><article-title>Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy</article-title><source>J Am Coll Cardiol</source><year>2002</year><volume>40</volume><fpage>278</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">12106932</pub-id></citation></ref><ref id="bib23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ciampi</surname><given-names>Q.</given-names></name><name><surname>Betocchi</surname><given-names>S.</given-names></name><name><surname>Losi</surname><given-names>M.A.</given-names></name></person-group><article-title>Abnormal blood-pressure response to exercise and oxygen consumption in patients with hypertrophic cardiomyopathy</article-title><source>J Nucl Cardiol</source><year>2007</year><volume>14</volume><fpage>869</fpage><lpage>875</lpage><pub-id pub-id-type="pmid">18022114</pub-id></citation></ref><ref id="bib24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>P.O.</given-names></name><name><surname>Morris-Thurgood</surname><given-names>J.A.</given-names></name><name><surname>Frenneaux</surname><given-names>M.P.</given-names></name></person-group><article-title>Vascular mechanisms of sudden death in hypertrophic cardiomyopathy, including blood pressure responses to exercise</article-title><source>Cardiol Rev</source><year>2002</year><volume>10</volume><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">11790265</pub-id></citation></ref><ref id="bib25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Omodani</surname><given-names>H.</given-names></name><name><surname>Kinugawa</surname><given-names>T.</given-names></name><name><surname>Ogino</surname><given-names>K.</given-names></name></person-group><article-title>Augmented exercise plasma noradrenaline with impaired chronotropic responsiveness in patients with hypertrophic cardiomyopathy</article-title><source>Clin Exp Pharmacol Physiol</source><year>1998</year><volume>25</volume><fpage>1018</fpage><lpage>1023</lpage><pub-id pub-id-type="pmid">9888000</pub-id></citation></ref><ref id="bib26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carl</surname><given-names>I.</given-names></name><name><surname>Ong</surname><given-names>H.</given-names></name><name><surname>Donnelly</surname><given-names>R.</given-names></name></person-group><article-title>Exercise in hypertrophic cardiomyopathy is associated with sympatho-adrenal imbalance</article-title><source>Int J Cardiol</source><year>2007</year><volume>116</volume><fpage>124</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">16843541</pub-id></citation></ref><ref id="bib27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knollmann</surname><given-names>B.C.</given-names></name><name><surname>Blatt</surname><given-names>S.A.</given-names></name><name><surname>Horton</surname><given-names>K.</given-names></name></person-group><article-title>Inotropic stimulation induces cardiac dysfunction in transgenic mice expressing a troponin T (I79N) mutation linked to familial hypertrophic cardiomyopathy</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>10039</fpage><lpage>10048</lpage><pub-id pub-id-type="pmid">11113119</pub-id></citation></ref><ref id="bib28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okeie</surname><given-names>K.</given-names></name><name><surname>Shimizu</surname><given-names>M.</given-names></name><name><surname>Yoshio</surname><given-names>H.</given-names></name></person-group><article-title>Left ventricular systolic dysfunction during exercise and dobutamine stress in patients with hypertrophic cardiomyopathy</article-title><source>J Am Coll Cardiol</source><year>2000</year><volume>36</volume><fpage>856</fpage><lpage>863</lpage><pub-id pub-id-type="pmid">10987611</pub-id></citation></ref><ref id="bib29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>T.B.</given-names></name><name><surname>Lin</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>C.C.</given-names></name></person-group><article-title>Effect of aging on gender differences in neural control of heart rate</article-title><source>Am J Physiol</source><year>1999</year><volume>277</volume><fpage>H2233</fpage><lpage>H2239</lpage><pub-id pub-id-type="pmid">10600841</pub-id></citation></ref><ref id="bib30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>G.</given-names></name><name><surname>Mechling</surname><given-names>E.</given-names></name><name><surname>Ewy</surname><given-names>G.A.</given-names></name></person-group><article-title>Clinical significance of early vs late hypotensive blood pressure response to treadmill exercise</article-title><source>Arch Intern Med</source><year>1992</year><volume>152</volume><fpage>1005</fpage><lpage>1008</lpage><pub-id pub-id-type="pmid">1580703</pub-id></citation></ref><ref id="bib31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Comess</surname><given-names>K.A.</given-names></name><name><surname>Fenster</surname><given-names>P.E.</given-names></name></person-group><article-title>Clinical implications of the blood pressure response to exercise</article-title><source>Cardiology</source><year>1981</year><volume>68</volume><fpage>233</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">7034937</pub-id></citation></ref><ref id="bib32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Irace</surname><given-names>C.</given-names></name><name><surname>Scavelli</surname><given-names>F.</given-names></name><name><surname>Carallo</surname><given-names>C.</given-names></name></person-group><article-title>Body mass index, metabolic syndrome and carotid atherosclerosis</article-title><source>Coron Artery Dis</source><year>2009</year><volume>20</volume><fpage>94</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">19293666</pub-id></citation></ref><ref id="bib33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zoghbi</surname><given-names>W.A.</given-names></name><name><surname>Enriquez-Sarano</surname><given-names>M.</given-names></name><name><surname>Foster</surname><given-names>E.</given-names></name></person-group><article-title>Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography</article-title><source>J Am Soc Echocardiogr</source><year>2003</year><volume>16</volume><fpage>777</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">12835667</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1"><label>Figure 1</label><caption><p>Percentage of males and females within each group demonstrating normal and abnormal blood pressure responses to exercise.</p></caption><graphic xlink:href="gr1"/></fig><fig id="fig2"><label>Figure 2</label><caption><p>Bar graph of adjusted means and 95% confidence interval of untransformed values, showing percentage change in hemodynamic parameters from resting to peak exercise. *<italic>P</italic> = .029.</p></caption><graphic xlink:href="gr2"/></fig><fig id="fig3"><label>Figure 3</label><caption><p>Mean rate of change in SBP in the groups during early exercise and at peak exercise. Values were adjusted for age, sex, body surface area, resting HR, and resting SBP.</p></caption><graphic xlink:href="gr3"/></fig><table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Clinical characteristics of subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><italic>MYH7</italic></th><th align="left">R92W<sub><italic>TNNT2</italic></sub></th><th align="left">Controls</th></tr></thead><tbody><tr><td>N</td><td align="char">51</td><td align="char">30</td><td align="char">68</td></tr><tr><td>Males, % (n)</td><td>35&#x000a0;(69)</td><td>12&#x000a0;(41)</td><td>31&#x000a0;(46)</td></tr><tr><td>Age, years</td><td>38&#x000a0;(17&#x02013;72)</td><td>34&#x000a0;(14&#x02013;66)</td><td>34&#x000a0;(17&#x02013;63)</td></tr><tr><td>Body surface area, kg/m<sup>2</sup></td><td>1.9&#x000a0;(1.3&#x02013;2.5)</td><td>1.7&#x000a0;(1.3&#x02013;2.1)</td><td>1.8&#x000a0;(1.3&#x02013;2.3)</td></tr><tr><td>LVM, g</td><td>182&#x000a0;(71&#x02013;477)</td><td>126&#x000a0;(48&#x02013;290)</td><td>122&#x000a0;(58&#x02013;272)</td></tr><tr><td>maxLVWT, mm</td><td>13.8&#x000a0;(7.7&#x02013;38.2)</td><td>11.6&#x000a0;(6.7&#x02013;30.0)</td><td>10.1&#x000a0;(7.1&#x02013;27.0)</td></tr><tr><td>Left atrial diameter, mm</td><td>35.8&#x000a0;(20.0&#x02013;65.0)</td><td>32.9&#x000a0;(21.0&#x02013;49.0)</td><td>30.6&#x000a0;(22.0&#x02013;45.0)</td></tr><tr><td>LV end-diastolic diameter, mm</td><td>44.0&#x000a0;(32.0&#x02013;52.0)</td><td>40.5&#x000a0;(33.0&#x02013;48.0)</td><td>44.0&#x000a0;(37.0&#x02013;60.0)</td></tr><tr><td>LV end-systolic diameter, mm</td><td>26.8&#x000a0;(17.0&#x02013;38.0)</td><td>22.7&#x000a0;(16.1&#x02013;33.2)</td><td>28.0&#x000a0;(21.0&#x02013;44.0)</td></tr><tr><td>Ejection fraction, %</td><td>70&#x000a0;(57&#x02013;81)</td><td>71&#x000a0;(61&#x02013;79)</td><td>65&#x000a0;(52&#x02013;75)</td></tr><tr><td>SV, mL</td><td>83&#x000a0;(33&#x02013;124)</td><td>78&#x000a0;(43&#x02013;103)</td><td>80&#x000a0;(48&#x02013;133)</td></tr><tr><td>Cardiac output at rest</td><td>6.2&#x000a0;(2.0&#x02013;11.3)</td><td>5.3&#x000a0;(3.3&#x02013;8.9)</td><td>6.0&#x000a0;(4.2&#x02013;10.9)</td></tr><tr><td>Resting HR, bpm</td><td>75&#x000a0;(60&#x02013;145)</td><td>72&#x000a0;(55&#x02013;118)</td><td>78&#x000a0;(48&#x02013;123)</td></tr><tr><td>SBP<sub>resting</sub>, mmHg</td><td>120&#x000a0;(80&#x02013;140)</td><td>110&#x000a0;(90&#x02013;130)</td><td>115&#x000a0;(90&#x02013;160)</td></tr><tr><td>DBP<sub>resting</sub>, mmHg</td><td>80&#x000a0;(60&#x02013;100)</td><td>70&#x000a0;(60&#x02013;90)</td><td>80&#x000a0;(60&#x02013;100)</td></tr><tr><td>Outflow tract gradient &#x0003e;30 mmHg</td><td>0&#x000a0;(0)</td><td>0&#x000a0;(0)</td><td>0&#x000a0;(0)</td></tr><tr><td>Systolic anterior motion of the mitral valve</td><td>4&#x000a0;(8)</td><td>0&#x000a0;(0)</td><td>0&#x000a0;(0)</td></tr><tr><td>MR = 1</td><td>18&#x000a0;(36)</td><td>4&#x000a0;(15)</td><td>4&#x000a0;(7)</td></tr><tr><td>MR = 2</td><td>1&#x000a0;(2)</td><td>1&#x000a0;(4)</td><td>1&#x000a0;(2)</td></tr><tr><td>NYHA 2</td><td>8&#x000a0;(16)</td><td>3&#x000a0;(11)</td><td>2&#x000a0;(3)</td></tr><tr><td>Atrial fibrillation</td><td>2&#x000a0;(4)</td><td>2&#x000a0;(7)</td><td>0&#x000a0;(0)</td></tr><tr><td>Hypertension diagnosis</td><td>7&#x000a0;(14)</td><td>0&#x000a0;(0)</td><td>2&#x000a0;(3)</td></tr><tr><td>maxLVWT &#x02265;30 mm</td><td>4&#x000a0;(8)</td><td>1&#x000a0;(3)</td><td>0&#x000a0;(0)</td></tr><tr><td>Syncope</td><td>4&#x000a0;(8)</td><td>3&#x000a0;(10)</td><td>2&#x000a0;(3)</td></tr><tr><td>% Families with SCD</td><td align="char">39</td><td align="char">57</td><td align="left">NA</td></tr></tbody></table><table-wrap-foot><fn><p><italic>Note:</italic> Values are given as median (range) for continuous variables and as numbers (percentage) for categorical variables. No individuals were above New York Heart Association (NYHA) class 2 or mitral regurgitation (MR) score 2&#x000a0;(according to Zhogbi et al.<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> 2003). NA = not applicable.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Blood pressure and HR response to exercise in R92W<sub><italic>TNNT2</italic></sub> and <italic>MYH7</italic> mutation carriers and noncarrier controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><italic>MYH7</italic></th><th align="left">R92W<sub><italic>TNNT2</italic></sub></th><th align="left">Controls</th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td>Total exercise time, seconds</td><td>528&#x000a0;(96&#x02013;1104)</td><td>379&#x000a0;(266&#x02013;937)</td><td>467&#x000a0;(171&#x02013;1319)</td><td>.339</td></tr><tr><td>MET, kcal/min</td><td>6.5&#x000a0;(2.3&#x02013;12.2)</td><td>6.5&#x000a0;(3.9&#x02013;14.7)</td><td>6.2&#x000a0;(2.9&#x02013;12.1)</td><td>.660</td></tr><tr><td>% HR achieved</td><td>96&#x000a0;(74&#x02013;104)</td><td>89&#x000a0;(56&#x02013;104)</td><td>94&#x000a0;(75&#x02013;108)</td><td>.417</td></tr><tr><td>%CR</td><td>88.0&#x000a0;(32.3&#x02013;141.2)</td><td>83.7&#x000a0;(24.8&#x02013;143.1)</td><td>89.4&#x000a0;(54.1&#x02013;118.5)</td><td>.487</td></tr><tr><td>HR<sub>peak</sub>, bpm</td><td>171&#x000a0;(129&#x02013;203)</td><td>169&#x000a0;(98&#x02013;211)</td><td>170&#x000a0;(123&#x02013;197)</td><td>.449</td></tr><tr><td>&#x00394;HR, bpm</td><td>92.0&#x000a0;(10&#x02013;140)</td><td>92.0&#x000a0;(28&#x02013;136)</td><td>90.5&#x000a0;(44&#x02013;137)</td><td>.499</td></tr><tr><td>Abnormal blood pressure response, any (%)</td><td>12&#x000a0;(24)</td><td>14&#x000a0;(48)</td><td>16&#x000a0;(24)</td><td>.021</td></tr><tr><td>Flat (%)</td><td>10&#x000a0;(20)</td><td>14&#x000a0;(48)</td><td>11&#x000a0;(16)</td><td>.018</td></tr><tr><td>Hypotensive (%)</td><td>2&#x000a0;(4)</td><td>0&#x000a0;(0)</td><td>5&#x000a0;(8)</td><td>.357</td></tr><tr><td>SBP<sub>peak</sub>, mmHg</td><td>160&#x000a0;(120&#x02013;230)</td><td>140&#x000a0;(100&#x02013;190)</td><td>160&#x000a0;(110&#x02013;220)</td><td>.064</td></tr><tr><td>&#x00394;SBP, mmHg</td><td>35&#x000a0;(0&#x02013;100)</td><td>30&#x000a0;(10&#x02013;60)</td><td>40&#x000a0;(5&#x02013;100)</td><td>.020</td></tr><tr><td>DBP<sub>peak</sub>, mmHg</td><td>90&#x000a0;(70&#x02013;120)</td><td>90&#x000a0;(50&#x02013;100)</td><td>90&#x000a0;(60&#x02013;120)</td><td>.589</td></tr><tr><td>&#x00394;DBP, mmHg</td><td>10&#x000a0;(&#x02212;20&#x02013;40)</td><td>10&#x000a0;(&#x02212;10&#x02013;30)</td><td>10&#x000a0;(&#x02212;20&#x02013;40)</td><td>.732</td></tr></tbody></table><table-wrap-foot><fn><p><italic>Note:</italic> Values are given as median (range) for continuous variables and as numbers (percentage) for categorical variables. <italic>P</italic>-values reflect differences between groups for quantile normalized data, adjusted for age, sex, resting mean arterial pressure, and resting HR. &#x00394; = change in parameter between resting and peak exercise; peak = parameter at peak exercise; % HR achieved = % of predicted maximal HR achieved by peak exercise.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl3"><label>Table 3</label><caption><p>Characteristics of individuals who experienced SCD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Families</th><th align="left">Sex</th><th align="left">Age, years</th><th align="left">Circumstances of SCD</th></tr></thead><tbody><tr><td>R92W<sub><italic>TNNT2</italic></sub>:</td><td/><td/><td/></tr><tr><td>&#x000a0;Ped 100</td><td>F</td><td>62</td><td>Physical exertion</td></tr><tr><td>&#x000a0;Ped 100</td><td>M</td><td>16</td><td>Physical exertion</td></tr><tr><td>&#x000a0;Ped 100</td><td>M</td><td>14</td><td>Physical exertion</td></tr><tr><td>&#x000a0;Ped 100</td><td>M</td><td>36</td><td>Physical exertion</td></tr><tr><td>&#x000a0;Ped 109</td><td>M</td><td>23</td><td>Physical exertion</td></tr><tr><td>&#x000a0;Ped 137</td><td>M</td><td>17</td><td>Physical exertion</td></tr><tr><td>&#x000a0;Ped 137</td><td>M</td><td>15</td><td>Physical exertion</td></tr><tr><td>&#x000a0;Ped 139</td><td>M</td><td>40</td><td>Physical exertion</td></tr><tr><td>&#x000a0;Ped 139</td><td>M</td><td>19</td><td>Physical exertion</td></tr><tr><td colspan="2" align="left">A797T<sub><italic>MYH7</italic></sub>:</td><td/><td/></tr><tr><td>&#x000a0;Ped 101</td><td>F</td><td>55</td><td>Washing dishes</td></tr><tr><td>&#x000a0;Ped 101</td><td>F</td><td>24</td><td>Upon return from work</td></tr><tr><td>&#x000a0;Ped 101</td><td>F</td><td>17</td><td>Emotional exertion</td></tr><tr><td>&#x000a0;Ped 101</td><td>M</td><td>22</td><td>Physical exertion</td></tr><tr><td>&#x000a0;Ped 104</td><td>M</td><td>40</td><td>Physical exertion</td></tr><tr><td>&#x000a0;Ped 131</td><td>M</td><td>23</td><td>Sedentary</td></tr><tr><td>&#x000a0;Ped 147</td><td>M</td><td>30</td><td>Physical exertion</td></tr><tr><td>&#x000a0;Ped 158</td><td>M</td><td>64</td><td>Physical exertion</td></tr></tbody></table><table-wrap-foot><fn><p><italic>Note:</italic> F = female; M = male.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl4"><label>Table 4</label><caption><p><italic>P</italic>-values and estimated odds ratio (OR) for abnormal blood pressure response in R92W<sub><italic>TNNT2</italic></sub> compared with <italic>MYH7</italic> carriers and noncarrier control individuals, adjusted for age, sex, resting mean arterial pressure, resting HR, and family relatedness</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Groups</th><th align="left">OR</th><th align="left">95% Confidence interval</th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td><italic>R92W</italic><sub><italic>TNNT2</italic></sub></td><td/><td/><td/></tr><tr><td>&#x000a0;<italic>MYH7</italic></td><td>3.03</td><td>1.13,&#x000a0;8.12</td><td>.029</td></tr><tr><td><italic>R92W</italic><sub><italic>TNNT2</italic></sub></td><td/><td/><td/></tr><tr><td>&#x000a0;Control</td><td>3.03</td><td>1.20,&#x000a0;7.68</td><td>.021</td></tr><tr><td><italic>MYH7</italic></td><td/><td/><td/></tr><tr><td>&#x000a0;Control</td><td>1.00</td><td>0.42,&#x000a0;2.37</td><td>1.000</td></tr></tbody></table></table-wrap></floats-wrap></article> 